Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody...

Full description

Bibliographic Details
Main Authors: Surana, Rishi (Author), Mihm, Martin C (Author), Angelini, Alessandro (Contributor), Weiner, Louis M (Author), Dranoff, Glenn (Author), Zhu, Eric Franklin (Contributor), Opel, Cary Francis (Contributor), Kwan, Byron Hua (Contributor), Kauke, Monique Jacqueline (Contributor), Moynihan, Kelly Dare (Contributor), Williams, Robert T. (Contributor), Yaffe, Michael B (Contributor), Irvine, Darrell J (Contributor), Wittrup, Karl Dane (Contributor), Gai, S. Annie (Author), Stephan, Matthias T. (Author), Kim, Jacob S. (Author)
Other Authors: Massachusetts Institute of Technology. Center for Materials Science and Engineering (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Gai, Shuning (Contributor), Stephan, Matthias (Contributor), Kim, Jacob S (Contributor)
Format: Article
Language:English
Published: Elsevier, 2016-12-15T19:25:49Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items